Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application

Hepatology

Volumn 43, Issue 6, 2006, Pages 1346-1353

  Kneteman, Norman M ^a,c,f   Weiner, Amy J ^b   O'Connell, John ^d   Collett, Marc ^e   Gao, Tiejun ^c   Aukerman, Lea ^b   Kovelsky, Rosemary ^b   Ni, Zhi Jie ^b   Hashash, Ahmad ^b   Kline, Janine ^b   Hsi, Belinda ^a   Schiller, Daniel ^a   Douglas, Donna ^a   Tyrrell, D Lorne J ^a,c   Mercer, David F ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

^c KMT Hepatech Inc   (Canada)

^d WYETH RESEARCH   (United States)

^e ViroPharma Incorporated   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; CILUPREVIR; ENZYME INHIBITOR; HCV 371; RNA POLYMERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATOCYTE TRANSPLANTATION; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA ISOLATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CARBAMATES; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON ALFA-2B; MACROCYCLIC COMPOUNDS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PROBABILITY; QUINOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; THIAZOLES; TREATMENT OUTCOME;

EID: 33745543683     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21209     Document Type: Article

References (19)

1. Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125-143.
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
3. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-2099.
4. Pearlman BL. Hepatitis C treatment update. Am J Med 2004;117:344-352.
5. Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990;62:447-456.
6. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-933.
7. Gopalsamy A, Aplasca A, Ciszewski G, Park K, Ellingboe JW, Orlowski M, et al. Design and synthesis of 3,4-dihydro-1H-(1)-benzothieno(2,3-c) pyran and 3,4-dihydro-1H-(3,4-b)benzofuran derivatives as non-nucleoside inhibitors of HCVNS5B RNA dependent RNA polymerase. Bioorg Med Chem Lett. 2006;16:457-460.
8. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 2003;77:3007-3019.
9. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-189.
10. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004;279:17508-17514.
11. Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004;48:2260-2266.
12. Thibeault D, Bousquet C, Gingras R, Lagace L, Maurice R, White PW, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 20041;78:7352-7359.
13. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001;75:4614-4624.
14. Viropharma, Inc. Press Release, (www.viropharma.com) July 15, 2003.
15. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
16. Dalgard O, Bjoro K, Helium KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004;40:1260-1265.
17. De L, V, Trimoulet P, Winnock M, Bernard PH, Bourliere M, Portal I, et al. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol 2002;36:819-826.
18. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
19. Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE, et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A 2002;99:14416-l4421.